C.J. Ryan

Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer

P. Francis, O. Pagani, G. F. Fleming, B. Walley et autres

BACKGROUND: The Suppression of Ovarian Function Trial (SOFT) found adding ovarian function suppression (OFS) to tamoxifen (T) reduced breast cancer recurrence, and exemestane (E)+OFS further reduced recurrence. A combined analysis of SOFT and TEXT showed a significant reduction in distant recurrence with …

au, us, ca, it, hu, es, pe, fr, ch, de (code pays fourni par la source)

2463P Efficacy and safety of rucaparib in patients with BRCA-mutated metastatic castration-resistant prostate cancer after crossover from physician’s choice therapy on TRITON3

C.J. Ryan, K. Fizazi, Alan Haruo Bryce, N. Alimohamed et autres

us, fr, it, es, gb (code pays fourni par la source)

Abiraterone in metastatic prostate cancer without previous chemotherapy

S. Ng, H. Van Poppel, E. Winquist, K. Fizazi et autres

Background: Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration-resistant prostate cancer after chemotherapy. We evaluated this agent in patients who had not received previous chemotherapy. Methods: In this double-blind study, we randomly assigned 1088 patients to …

564 Assessment of corticosteroid (CS)-associated adverse events (AEs) with long-term (LT) exposure to low-dose prednisone (P) given with abiraterone acetate (AA) to metastatic castration-resistant prostate cancer (mCRPC) patients (pts)

K. Miller, K. Chi, J.S. de Bono, K. Fizazi et autres